Perrigo's Q1 Results Offer Scant Support To Promote Its 'Self-Care' Turnaround

President and CEO Murray Kessler attempts to temper expectations before investor day on May 9 saying Perrigo's turnaround under strategy implemented after he joined firm in November is in its early days. Private label leader, however, will report another step in its move to return to being consumer product-focused: agreement to sell its animal health business to PetIQ for $185m cash.

Hitting bigger business target

Perrigo Co. PLC won't have strong quarterly results to help management convince investors about their turnaround strategy that swings on a change the firm says started during its latest quarter, moving from health care to self-care.

However, during its first-quarter results and investor day conference on May 9, the Dublin-based firm, which has remained the dominant OTC drug private label and store brand provider during its lengthy slump in net income and earnings, will report another step in its move to return to being consumer product-focused

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Recordati Relying On OTC To Act As ‘Booster’ To Growth

 
• By 

In categories like cough & cold and gastrointestinal, OTC products have a pivotal role to play in helping Recordati hit its sales targets for the 2025-2027 period.

Bayer Consumer Health Delivers ‘Balanced’ Q1

 
• By 

With sales gains across most of its regions and product categories, Bayer Consumer Health got off to a good start to the year.

People On The Move: Appointments at Opella, NèreS, Haleon

 
• By 

A round-up of the latest consumer health industry moves: Opella names France head; NèreS elects president; Haleon has new Saudi GM.

C&D Taps Hand Sanitizer Category With Touchland

 

Deal totaling as much as $880m extends C&D into additional product category with a brand it says is the fastest growing in the US hand sanitizer category and No. 2 brand in the category overall.

More from Health

EU Parliament Calls For Review Of Wastewater Directive’s Impact On Pharma Sector

 
• By 

At a recent plenary session the European Parliament adopted a resolution calling on the European Commission to “conduct a new and comprehensive assessment” of the impact of the revised Urban Wastewater Treatment Directive on the pharmaceutical sector.

Bayer Consumer Health Delivers ‘Balanced’ Q1

 
• By 

With sales gains across most of its regions and product categories, Bayer Consumer Health got off to a good start to the year.

People On The Move: Appointments at Opella, NèreS, Haleon

 
• By 

A round-up of the latest consumer health industry moves: Opella names France head; NèreS elects president; Haleon has new Saudi GM.